1 2 3 4 5 257
Number of results: 5132

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2019-01-22 Editas Medicine (USA - MA) president and CEO resignation Resignation
2019-01-22 Crispr Therapeutics (Switzerland - UK) Probiogen (Germany) novel in vivo delivery modalities for CRISPR/Cas9 research - development Research agreement
2019-01-21 GE Healthcare (USA - WI) G-CON Manufacturing (USA - TX) manufacturing platform suitable for early-stage clinical or commercial production of cell therapy and viral vector collaboration Technology - Services Collaboration agreement
2019-01-18 Celgene (USA - NJ) Kyn Therapeutics (USA - MA) immuno-oncology therapies, aryl hydrocarbon receptor (AHR) antagonist program, kynurenine-degrading enzyme (“Kynase”) program development - licensing Cancer - Oncology Licensing agreement
2019-01-18 Novartis (Switzerland) University of Oxford’s Big Data Institute (BDI) (UK) artificial intelligence programs multiple sclerosis, dermatology, rheumatology collaboration Technology - Services Collaboration agreement
2019-01-17 Asceneuron (Switzerland) chairman nomination Neurodegenerative diseases Nomination
2019-01-17 Imabiotech (France) Metabrain Research (France) measurement of tissue distribution, pharmacokinetic and pharmacodynamic (PK/PD) drug effects in preclinical metabolic disorders models metabolic age-related diseases such as NASH, diabetes, sarcopenia and related immuno-inflammatory disorders collaboration Metabolic diseases - Technology - Services Collaboration agreement
2019-01-15 Biomunex Pharmaceuticals (France) Sanofi (France) BiXAb® technology licensing Technology - Services Licensing agreement
2019-01-14 Calliditas Therapeutics (Sweden) vice-president Renal dise nomination Renal diseases - Rare diseases - Kidney diseases Nomination
2019-01-08 Celgene (USA - NJ) Evotec (Germany) neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease R&D - research - development Neurodegenerative diseases Milestone
2019-01-08 4D Pharma (UK) non-executive director nomination Nomination
2019-01-08 Calliditas Therapeutics (Sweden) vice president nomination Nomination
2019-01-07 4D Pharma (UK) MD Anderson Cancer Center (USA - TX) MRx0518 solid tumors collaboration Cancer - Oncology Clinical research agreement
2019-01-07 PTC Therapeutics (USA - NJ) chief scientific officer, chief technical operations officer nomination Rare diseases - Genetic diseases Nomination
2019-01-04 Sanofi (France) BioNTech (Germany) up to five cancer immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs).
  • research - development - licensing
Cancer - Oncology R&D agreement
2019-01-04 BioNTech (Germany) member of the board, vice president nomination Cancer - Oncology - Infectious diseases Nomination
2019-01-04 Galapagos (Belgium) Fibrocor (Canada) small molecule inhibitor program idiopathic pulmonary fibrosis (IPF), fibrotic diseases of the lung and other organs collaboration Fibrotic diseases Collaboration agreement
2019-01-04 Esperion Therapeutics (USA - MI) Daiichi Sankyo (Japon) bempedoic acid and the bempedoic acid / ezetimibe combination pill licensing Licensing agreement
2019-01-04 Sana Biotechnology (USA - WA)
  • CAR-T cell therapy
nomination Resignation
2019-01-04 Biogen (USA - MA) Skyhawk (USA - MA) SkySTAR™ technology platform neurological diseases licensing Neurological diseases Licensing agreement